Latest News - Alnylam Pharmaceuticals
Top Corporates Hub
Alnylam Pharmaceuticals
Alnylam Issues 2025 Corporate Responsibility Report
19.05.2026 12:30
CAMBRIDGE, Mass., May 19, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, "Accepting Challenges to Improve the Health of Humanity," which remains central to Alnylam’s strategy and is embedded across six
Why Pfizer Stock Still Looks Deeply Undervalued In 2026
18.05.2026 09:28
FDA leadership shake-up update and what it means for Pfizer: valuation, dividend yield, and Padcev growth.
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation
18.05.2026 08:05
Alnylam Pharmaceuticals (NasdaqGS:ALNY) reported new Phase 3 HELIOS-B analyses for vutrisiran in ATTR-CM. The data show reductions in all-cause mortality and cardiovascular events, including in high-risk subgroups. Safety findings support a favorable profile for vutrisiran, the first and only approved TTR silencer for ATTR-CM. Alnylam is also launching the DemonsTTRate real-world outcomes study to assess long-term impact in routine clinical practice. Alnylam focuses on RNA interference...
Morgan Stanley Increases Price Goal on Alnylam Pharmaceuticals, Inc. (ALNY)
13.05.2026 17:55
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 1, Morgan Stanley bumped up its price goal on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $370 from $360. It maintained an Equal Weight rating on the stock. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported first quarter 2026 financials, delivering global […]
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
13.05.2026 16:40
Alnylam Pharmaceuticals, Inc. (ALNY) Bank of America Global Healthcare Conference 2026 May 13, 2026 1:40 PM EDTCompany ParticipantsJeffrey Poulton - CFO...
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 10
13.05.2026 15:35
Presenter SpeechTazeen Ahmad Good morning. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Alnylam
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
12.05.2026 06:30
CAMBRIDGE, Mass., May 12, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), adding to the growing body of evidence supporting vutrisiran and reinforcing the durability of transthyretin (TTR) knockdown and its well-characterized safety profile. Vutrisiran is the first and onl
Alnylam Presents HELIOS-B Data At Heart Failure 2026 Supporting Vutrisiran As First-Line Treatment Across Broad ATTR-CM Populations
12.05.2026 02:48
− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies –− Pooled Analysis of Over 25,000
Alnylam to Webcast Presentations at Upcoming Investor Conferences
07.05.2026 12:00
CAMBRIDGE, Mass., May 07, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
07.05.2026 11:00
CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Mark R. Soued, MBA, as Chief Commercial Officer (CCO). Mr. Soued brings more than two decades of commercial leadership across global biopharmaceutical organization
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
04.05.2026 12:30
CAMBRIDGE, Mass., May 04, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain.
Discover 3 Stocks That Might Be Trading Below Estimated Value
01.05.2026 11:38
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
3 Companies That May Be Priced Below Their Estimated Value
30.04.2026 11:38
Over the last 7 days, the United States market has remained flat, yet it is up 28% over the past year, with earnings forecast to grow by 16% annually. In such a climate, identifying stocks that may be priced below their estimated value can offer investors opportunities for potential growth as they seek companies with strong fundamentals and promising prospects.
Alnylam: Q1 Earnings Snapshot
30.04.2026 08:10
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Alnylam Pharmaceuticals Inc. on Thursday reported first-quarter net income of $206 million, after reporting a loss in the same period a year earlier. The...
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
30.04.2026 08:03
− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million , Driven Primarily by Total TTR Revenues of $910 Million –− Reiterates 2026 Financial Guidance, Including Combined...
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
30.04.2026 08:03
− Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million , Driven Primarily by Total TTR Revenues of $910 Million –− Reiterates 2026 Financial Guidance, Including Combined...
Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
29.04.2026 13:15
Beyond analysts' top-and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial
27.04.2026 07:10
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 New Contenders for S&P 500 Index. On April 17, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) provided an update on its experimental drug, ALN-4324. Currently in its Phase 2 clinical trial, the company’s experimental RNAi therapeutic drug aims at treating type 2 diabetes. The trial involves a triple-blind, […]
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
23.04.2026 14:00
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.